Podcasts about biib

We are on the Hill Advocating for a better future – Sprint, DREEM, Travel & NET -  #S10e162 Tuesday, February 25, 2025 - Week 9   ADVOCACY - Thank you Jessica, Jaime and Vicky for repping SRF at ELF RD Week https://www.linkedin.com/posts/curesyngap1_raredc2025-syngap1-advocacy-activity-7300237949831368705-FIRS    SPRINT4SYNGAP - April 26, 2025 Webinar: cureSYNGAP1.org/S4S25 Guide: cureSYNGAP1.org/S4SGuide   LEVERAGE ON OUR GRANTS #Finland #Missense: https://www.linkedin.com/posts/graglia_kulttuurirahastontuella-skr2025-syngap1-activity-7296289488912191489-rWl-/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAD8f4B7JC4TMss45Q8hrsq5kiceI0Z8HE   STUDY OF THE WEEK - Email syngap-study@beacon.bio Dreem: https://curesyngap1.org/resources/studies/beacon-dreem-eeg-device-study-in-syngap1/    Study Tracker page: https://docs.google.com/spreadsheets/d/1oQLNi85AUbISmcW0KbsgGn4cBK_4MNuvwGlKUUKLyIQ/edit?usp=sharing    IMPACT REPORT NL43 cureSYNGAP1.org/NL43    ONLINE DID YOU KNOW We have a calendar now! https://curesyngap1.org/calendar/ Brochure is updated: cureSYNGAP1.org/Brochure  YouTube - Adding Family Day Talks - https://www.youtube.com/playlist?list=PLjpr3a14_ls2ummdbWyUdvRpMcQBlRXy2    COMPANY OF THE WEEK - Stoke & Biogen! STK ($0.45Bn) partners with BIIB ($20.5Bn) https://investor.stoketherapeutics.com/news-releases/news-release-details/biogen-and-stoke-therapeutics-enter-collaboration-develop-and   #SpecialNeedsTRAVEL e31 of SYNGAP1 Stories. Navarros - cureSYNGAP1.org/Stories  Comments on YouTube are great, see this presentation by SRF's Heather on travel… https://youtu.be/c7S7q_gK4Bk?si=wM4Ter_q8-37Yg8V   RESEARCH UPDATE There are 318 papers on or related to SYNGAP1 since 1998, but 54 of those are in 2024!  So far 10 (Coller included) for 2025. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.1998-2025&sort=pubdate&timeline=expanded Frazier paper on NET: https://onlinelibrary.wiley.com/doi/10.1002/aur.3290   VOLUNTEER SPOTLIGHT Toby and John Brimsek are tireless.  Thank you. https://curesyngap1.org/team/volunteers/emily-brimsek-phd/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/   CONFERENCE Pre-register now: December 4 & 5 – https://cureSYNGAP1.org/Pre25  REGISTER FOR BRAIN DONATION via https://www.autismbrainnet.org/ https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1486227/full   SOCIAL MATTERS - 3,937 LinkedIn.  https://www.linkedin.com/company/curesyngap1/ - 1.28k YouTube.  https://www.youtube.com/@CureSYNGAP1  - 11.5k Twitter https://twitter.com/cureSYNGAP1 - 46.6k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources    Podcasts, give all of these a five star review! https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917   Episode 162 of #Syngap10  #CureSYNGAP1 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness  #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GeneChat #F78A1

S&P Futures are trading lower this morning with the markets in a holding pattern ahead of this morning CPI report. President Trump is expected to make an announcement today on tariffs and he is likely to use a 1930's trade law as the basis for reciprocal U.S. tariffs. Fed Chairman Jerome Powell will be continuing his testimony on Capitol Hill today. Earning beats this morning from BIIB, CVS & GNRC and last night from GILD, DASH, & AIG shares are trading higher. After the bell today CSCO, APP, EQIX HOOD, RDDT & UPWK to report. Oil prices are falling after last night's AOI data displayed a big build in inventories.

David kicks off 2025 by revisiting five timeless lessons drawn from classic episodes spanning nearly a decade of weekly podcasts—now approaching 500 consecutive weeks of fresh content. Reaching back to 2016 and beyond, he rediscovers core investing principles: the surprising advantage of never selling, the folly of waiting for dips, the power of choosing stocks of stellar employers, and how great leaders transform intuition into intentional culture. Revisiting stories of Warren Buffett, Danny Meyer, and exceptional stock picks like Amazon and Nvidia, this episode delivers valuable, enduring truths for investors both new and seasoned. Host: David Gardner Producer: Dez Jones Companies Mentioned: AAPL, AMZN, ARM, BIIB, CRM, GOOG, META, NFLX, NVDA, TSLA

We speak with Sheyong Tan, Co-Founder of BiiB, a wellness tech startup that's changing the game in Malaysia's fitness landscape. From Malaysia's largest running league, RUNLIGA, to scalable corporate wellness solutions, BiiB combines community and innovation to redefine employee engagement and health. Sheyong shares his journey from R&D engineer to entrepreneur, explaining how BiiB's platform integrates fitness, community, and technology for a unique wellness experience.

On this week's Biotech Hangout, hosts Eric Schmidt, Josh Schimmer, Dawn Bell, Brad Loncar, Tim Opler, Sam Fazeli and Paul Matteis kick off the show by discussing CPI data and how inflation is impacting the $XBI, with analysts hopeful that stability will bring lower interest rates soon. The hosts cover the obesity market, providing updates on new datasets, such as findings from $LLY and $NVO, which indicate promising results in liver fat reduction and potential fibrosis reversal with GLP1+ agents. They also discuss competitive dynamics and investor sentiment of the obesity market and highlight the involvement of various players, including new startups and established pharma companies. In addition, the hosts share updates on Alzheimer's treatments, including takeaways from the EULAR meeting and $LLY's lecanemab panel, alongside the competitive landscape between $LLY, $ESAIY and $BIIB. The hosts also explore the role of patient advocacy within the biotech industry, focusing on $PFE's DMD study and $SRPTA's upcoming PDFUA, the role that patient advocacy groups have on regulatory decisions,  and the impact these groups have on influencing industry standards and guidelines. *This episode aired on June 14, 2024.

Rodinným táborem terezínských Židů v Auschwitz-Birkenau (Osvětim-Březinka) prošlo asi 17 500 lidí, nacismus jich přežilo méně než deset procent. Co víme o rodinném táboře, označovaném také jako „familienlágr“ či „úsek BIIb“? Co víme o osudech jeho obyvatel?

Rodinným táborem terezínských Židů v Auschwitz-Birkenau (Osvětim-Březinka) prošlo asi 17 500 lidí, nacismus jich přežilo méně než deset procent. Co víme o rodinném táboře, označovaném také jako „familienlágr“ či „úsek BIIb“? Co víme o osudech jeho obyvatel?Všechny díly podcastu Historie Plus můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Biogen's Q4 2023 earnings call, unedited

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen's next shot at an Alzheimer's treatment. - Why companies can't “muscle their way” into making new molecules. - How NVIDIA could change drug development.  - Moderna's vaccine strategy Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX Host: Deidre Woollard Guest: Karl Thiel Producer: Ricky Mulvey Engineer: Tim Sparks Learn more about your ad choices. Visit megaphone.fm/adchoices

S&P Futures are positive ahead of tomorrow's CPI and Wednesday's FOMC announcements. The ECB and the BOJ will also be having meetings this week on monetary policy. There is speculation that Chinese regulators may lower the medium-term lending facility. This afternoon Oracle will be releasing earnings. BIIB receives approval for it's Alzheimer treatment. European markets are trading higher this morning and Oil is down 2% in the pre-market.

Axsome Therapeutics (AXSM) stock price hit a 52-week high recently. Axsome Therapeutics (AXSM) announced that the drug AXS-05 phase 3 trial met endpoints. The drug significantly delayed the relapse of agitation symptoms in Alzheimer's disease patients. 66% of patients had improved agitation at two weeks and 86% at five weeks. George Tsilis compares AXSM to BMY, LLY, BIIB, and SAVA.

One of the most powerful private companies in the world is also one of the most secretive. Michael Forsythe is an investigative reporter for The New York Times and co-author of the new book “When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm.” Forsythe joined Ricky Mulvey to discuss: - Why Fortune 500 companies pay millions of dollars for the firm's advice - What “The Carnegie Way” meant for US Steel - McKinsey's relationship with the FDA and what it means for drugmakers Companies mentioned: X, BIIB, ALL, DIS, WMT, PNGAY Host: Ricky Mulvey Guest: Michael Forsythe Engineer: Dan Boyd

Straight from Benzinga newsdesk, host Brent Slava brings you the market news and stocks to watch.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659Hosts:Brent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga NewsdeskMichael O'Connor Reach out to Michael at michaeloconnor@benzinga.comBenzinga Strategy Development pro.benzinga.com$GM $GIIB $CLF $COOK $OUSTGeneral Motors (GM) - Shares were up about 4% in Tuesday's pre-market session following better-than-expected quarterly results and strong guidance. Ford (F) will report quarterly results on Wednesday after market close.Biogen (BIIB) - The company reported a beat on both the top- and bottom-lines for its third-quarter results. Biogen raised its fiscal year guidance. The stock traded up modestly, less than 1%.Cleveland-Cliffs (CLF) - One of Tuesday morning's big earnings-related losers. Shares were down about 11% following worse-than-expected quarterly earnings.Traegar (COOK) - Shares may see increased attention following a deal in the barbeque manufacturer space. Weber (WEBR) received a go-private offer at $6.25 per share. Weber shares were up about 30% on the news; Traeger shares traded up about 3%.Ouster (OUST) - A play on a favorable call by a sell-side analyst. Rosenblatt's Kevin Cassidy called Ouster "a leader in digital LiDAR technology" and began coverage on the stock with a Buy rating. We're always looking for ways to make this content better!If you have ideas for stocks we should cover or have feedback about the info or presentation, please drop us a line at newsdesk@benzinga.com or aslicoskun@benzinga.comUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Anavex Life Sciences (AVXL) announced a presentation of phase 2B/3 Anavex 2-73-AD-004 at clinical trials on Alzheimer's Disease Congress 2022 and findings will be published in a peer reviewed journal. Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company that develops therapeutics for neurodegenerative and neurodevelopmental disorders. Their lead compound Anavex2-73 is being developed to treat Alzheimer's, Parkinson's, and other central nervous system diseases. George Tsilis weighs in on how AVXL compares to BIIB, ESALY, and LLY.

Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks. (1:00) - Should You Continue To Invest In Growth Stocks? (6:10) - Understanding FANG During A Down Market (17:45) - Should You Be Buying The Dip Or Staying On The Sidelines? (29:00) - Have A Plan That Works For Your Investment Timeframe (34:50) - Episode Roundup: XOM, META, NVDA, MSFT, UNH, CNC, BIIB, LLY, ARKK

Volkswagen spun off its investment in Porsche for the first big name IPO of 2022. It only took until late September!  (0:18) Dylan Lewis and Tim Beyers discuss:  - Why Porsche is going public while other companies are holding off.  - Down rounds in the private markets.  - Promising results for Biogen's Alzheimer's treatment. Mortgage rates have doubled in the past year. (13:33) Deidre Woollard and Matt Argersinger look at the ripple effects and which companies could benefit from the shift. Companies mentioned: P911, VWAPY, RACE, BIIB, HD, Z, AOS, WSO, OPEN, LOW Host: Dylan Lewis Guests: Tim Beyers, Matt Argersinger, Deidre Woolard Producer: Ricky Mulvey Engineers: Rick Engdahl, Tim Sparks

Justin Nielsen and Irusha Peiris discuss how to avoid getting chopped up in a prolonged bear market. When a bear market persists, preservation of capital becomes even more important. We also get a surprise visit from hedge fund manager Jim Roppel. He discusses the opportunities that come after bear markets and current stocks showing leadership qualities including Biogen (BIIB), Eli Lilly (LLY), Aspen Tech (AZPN), Enphase (ENPH), and ShockWave (SWAV). For the video version, visit investors.com/podcast.

Prothena (PRTA) stock price today was up over 87%. Prothena is a late-stage clinical company engaged in the protein dysregulation. Their pipeline includes Parkinson's disease and Alzheimer's therapies. The PRTA stock was upgraded following positive data from Biogen (BIIB). George Tsilis weighs in on the BOFA analyst note that stated Prothena trial result is a big milestone in the treatment of Alzheimer's disease.

Featuring ABOS ACCD APRN BEAT BIIB CANO FIVE FREY FSLR NFLX NNOX PINS PLTR PRTA PYPL RUM TOPS Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

S&P Futures after being positive all morning, futures have just gone negative. There are a host of companies scheduled to release their earnings this morning including NTRS, NDAQ, BKR, BIIB, and ABT. After the bell today we will be hearing from SLG, AA, UAL, EFX, LVS, DFS, CSX, CCI, and TSLA. After the opening bell this morning we have economic reports on Existing Home Sales and the official EIA stockpiles report. News reports indicate that mortgage demand has dropped to a 22 year low.

Video Sponsor - http://workinbiotech.com/ In this episode, I go through a company called Vaxxinity, who are trying to develop vaccines for the treatment of various different diseases. They have a novel vaccine platform whereby they hope to induce both a humoral and T-cell response to specific proteins in various indications. One of their near-term readouts is a Phase 1 Part 2 data release from their UB-312 program in Parkinson Disease. This treatment is able to induce anti-α-synuclein antibodies, but I compare their data to two other programs that are further along to explain why they might not achieve material improvements in motor function in PD disease patients. In this episode, I also touch on $SIOX, $BIIB and $ACHV. Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

Biogen (BIIB) is coming off lows after positive news regarding their new Alzheimer's treatment drug, says George Tsilis. He talks about how BIIB has been upgraded to overweight Fromm equal weight at Wells Fargo. He also goes over how investors are not valuing royalty streams coming in properly from BIIB. He then demonstrates an example trade using BIIB. Tune in to find out more.

Featuring ABT ACET ALLK AMH APTS BBIO BIIB CALX CONN CPOP CSCO DADA (short) EFOI GDDY GILD HPQ ISIG MFIN MU PLAB PLTR RAD TRT VSCO WDC WEJO Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

As Q2-2021 earnings season comes to a close, I decided to do a recap on multiple biotech companies I'm interested in, providing updates from each one's Q2 report. Commercial-stage biotech continues to be a risky place to invest, but there are some bright spots we can look towards that I'll share in this episode. Here is the breakdown: $BIIB - 00:45 $BCEL - 8:36 $AUPH - 15:57 $TGTX - 18:50 $KPTI - 24:00 $CRIS - 26:52 $BTAI - 30:20 $RGNX - 32:50 $MDGL - 36:39 $VKTX - 39:30 $SAVA - 41:18 $FDMT - 46:00 $SELB - 47:40 Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

This week on the podcast Agustin discusses the recent pushback on the FDA's decision of Biogen's new Alzheimer's Drug and what that means for the future of neuroscience research and Medicare solvency. He also shares what could be a momentous event for one neuroscience company in particular and finally concludes the episode talking about Covid and what the future holds with the emergence and domination of the Delta variant.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

Rozhovor s Jánem Hájkem, portfolio manažerem fondu Top Stocks a Erste Stock Biotec, o investování do biotechnologického sektoru, v čem je tento sektor specifický, jak probíhá schvalovací proces léků,  khe hledat nejlepší zdroje informací, čeho by se začínající investoři měli vyvarovat nebo kde vidí Ján největší investiční příležitosti.AKCIE: AGIO, BIIB, BMY, BMRN, SRPT, FIXX, IPHA, JNCE, KDNY, VYGR, XNCR, ZGNX, BHVN, EXAS, GH, Allergan (už neexistuje, je součástí Abbvie – ABBV), AMRN, Valeant (nyní se jmenuje Bausch Health Companies – BHC). Odkaz na seznam akcií v Honzově portfoliu, tipy na knihy nebo biotechnologické podcasty. BIO: Ján působí na akciovém trhu od roku 1994, původně jako akciový analytik, portfolio manažer a proprietary trader. Manažerem podílového fondu Top Stocks je od jeho založení v srpnu 2006, kdy nastoupil do společnosti Erste Asset Management ČR. V současné době je hodnota fondu téměř 19 miliard Kč a má přes 70 000 klientů (k 30.  listopadu 2020). Tento fond investuje do koncentrovaného portfolia tvořeného přibližně 25 společnostmi, které jsou obchodované na trzích v USA a Evropě a které jsou vybírány s ohledem na jejich dlouhodobý růstový potenciál.V PODCASTU SE DOZVÍTE:Složení portfolia fondu Top Stocks (1:27)Složení portfolia Erste Stock Biotech (3:09)Co ho nejvíce lákalo na biotechnologickém sektoru (4:29)Výhody biotechnologického sektoru (8:35)Rozdíl mezi biotechnologiemi a farmacií (11:57)V čem je biotechnologický sektor specifický (13:58)Financování biotechnologických společností (17:20)Portfolio poručíka Dana (19:49) Léky pro širší veřejnost nebo "orphan drungs"? (23:50)Schvalovací proces léků & FDA (29:57)Rozklíčování genetických informací (40:51)Problém při vývoji léků (42:19)Problém schválení léků na Alzheimera (43:55)Patenty (55:24)R&D investice (1:02:10)Management a jaké vlastnosti u něho hledat (1:05:04)Známí investoři, kteří investují do biotechnologických společností (1:06:08)Partnerství - je to výhoda nebo nevýhoda? (1:08:23)Analýza biotechnologických akcií a jak na ní (1:12:27)V jaké vývojové fázi investuje Ján do společnosti (1:15:39)Jak analyzuje akcii v rané fázi vývoje (1:23:33)Kde hledat kvalitní zdroje informací (1:24:11)Kde vidí zajímavé investiční příležitosti (1:32:00)Čemu by se měli začínající investoři vyhnout (1:37:48)Čím se řídí při investování do biotechnologických akcií (1:42:57)V čem dělají investoři nejčastěji chybu (1:45:56)Společnosti v portfoliu (1:48:00)Nenechte si ujít letošní ročník České investiční konference, který proběhne 8. a 9. listopadu 2021 online. Program naleznete zde.Partnerem podcastu je Strike.Market, alternativní data pro vaše investice.Vaše zpětná vazba je pro mě důležitá. Máte-li k podcastu jakékoliv poznámky, zašlete mi je, prosím, na lenka@schanova.com. 

Geographic Atrophy is a progressive disease that leads to degeneration of the macula of the eye. Many companies have tried to develop therapies given the large market opportunity, but have been met with failure. This has not stopped new arrivals from trying their hand at improving patient outcomes. In this episode, I focus on the following companies: IONS, APLS, GMTX and CBIO. The major readout among them is that of APLS, happening in September and if successful, might bring new life into the sector. I also touch on updates from BIIB, ALXO and HEPA. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

Liz and Jenny take live tweets on trade ideas. They talk earnings trades and smoke patterns, and discuss big lizard management when the short strike is challenged.  Featured symbols include: BIIB, DOW, LUV, CLF, and PZZA

Liz and Jenny take live tweets on trade ideas. They talk earnings trades and smoke patterns, and discuss big lizard management when the short strike is challenged.  Featured symbols include: BIIB, DOW, LUV, CLF, and PZZA

Subsribe to All Benzinga Podcasts here: https://www.benzinga.com/podcasts On Today's PreMarket Prep: - Now We Know Why Moderna Stock Has Been Rallying $MRNA - Biogen's $BIIB alzeheimer's drug is in trouble - More bad news for Didi $DIDI FEATURED GUEST: Todd Gordon, CNBC Contributor and Founder of Trading Analysis 40:00 Meet the Hosts: Dennis Dick Twitter: https://twitter.com/TripleDTrader Joel Elconin Twitter: https://twitter.com/Spus https://www.premarketprep.com/ Spencer Israel Twitter: https://twitter.com/sjisrael BENZINGA YOUTUBE:

US equity markets lower today though no clear catalyst to the risk off trade. Themes discussed today includes peak growth, treasury yield movement, the delta variant and a smattering of corporate news. Tickers mentioned: KSU, GOOGL, BIIB

It's Thursday, June 24th, 2021. I'm Hoda, Co-founder and CEO of Stock Card. This is what happened in the stock market today in less than 5 minutes.    Today I looked into a few good news that pushed the market indices into the green zone, discussed why Google's 3rd party cookie announcement pushed The Trade Desk stock (#TTD) up and researched why Biogen's stock (#BIIB) ended the day in the red.  

US markets mixed to higher this week with the biggest macro focus again on inflation following the hotter than expected CPI print. In this episode we discuss what investor sentiment is around the possiblity of future inflation and when any policy shift may take place. On the corporate side, rising input costs, supply chain woes and a smattering of earnings make the broadcast. Tickers Mentioned: CHWY, CMG, SBUX, BIIB, MSTR, AMC, GME

Featuring ACTG ADT AHT ATOM BIIB CLF CLNE CLOV CNP GENE GEO GNUS IQ JNPR M MARA NLOK PLBY PRTY RESN RIOT ROOT SDC SKLZ TIGR TLRY TWTR WPG WRAP Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

Thoughts on Biogen (BIIB), The Fed and Inflation & Apple (AAPL)

It's Monday, June 7th, 2021. I'm Hoda, Co-founder and CEO of Stock Card. This is what happened in the stock market today. I reviewed how investors' sentiment held the market back for one more day and announced an exciting new feature on Stock Card. I also covered the major Alzheimer drug news that launched Biogen's (#BIIB) stock and investigated a slight dip in UiPath's (#PATH) price in advance of its first earnings report.  

Hey folks, Jon Najarian down here in San Juan Puerto Rico at the convention center. Another Bitcoin talk. Yeah, you bet. Here's what you need to know before you go. Microsoft apparently winning approval to do that takeover of Nuance. widely anticipated but we're still watching those shares. Take a look also at Blackstone because they're buying a big data center. REIT or owner and that is QTS and that stock is up I think 20% QTS is today. Bang. Also G Three apparel maker G Three, making a very nice move after tripling up on profits. Wow. Then we've got a USCR that's concrete company being bought by Vulcan materials VMC and that stock USCR is up by old Let me see 26% That's right. 26%. And lastly BIIB we're going to be talking about this. I'll be talking about it on the halftime report from down here in Puerto Rico, because they have anticipated an approval today for their Alzheimer treatment. And we certainly hope because of the efficacy and safety, but they do get that today. I am Jon Najarian. I'll be on the Daily Crypto Byte at 10am. Eastern Time, and I'll also be on the three at three 3pm Eastern and of course, I'll be on with my friends back in the States on Halftime Report at noon Eastern see you then!

Featuring AI ASXC ATOM ATOS BIIB CCIV CLNE CLOV SCPR DOCU EMKR FUBO HYRE IHRT INFN NCLH NEXT NIO NKLA NNDM NOK PLBY PLTR PLUG (FCEL) RMED SKLZ SPCE SU UONE WISA XL Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

Alex Denner is the Founder & Chief Investment Officer of Sarissa Capital Management, an activist firm investing in opportunities created by the unique dynamics of the healthcare sector. Alex also has a background in biomedical engineering. The estimated Net Worth of Alexander J Denner is at least $4.11 Billion dollars as of 26 February 2021. Alexander Denner owns over 1,350,000 units of Biogen Inc stock worth over $4,110,207,300 and over the last 12 years he sold BIIB stock worth over $1,800,788. ————————————————————————— To learn more about this episode, including podcast transcripts and show notes, visit *salt.org/talks* ( http://salt.org/talks ) Moderated by Anthony Scaramucci.

Try Stock Alert for Just $1 https://learn.sharpertrades.com/p/basic-stock-alert-trading-signal/?product_id=1205664&coupon_code=BASIC1YTB Today we discuss our Trades of the Day AMD ARWR AVXL BIIB BL BMY CHWY CRSR CYH DNLI FEYE FTCH GE GPS HALO IPHI JD KNDI LI LYFT MAT NET NIO PHR PINS PLTR SAVE SE SELB UAA UBER XPEV ZM Watch this video to get the technical insights. Good trading! Sign up to our blog to receive trade ideas and market updates. learn.sharpertrades.com/blog #Trading #DayTrading #SwingTrading Trading Risk Disclaimer All the information shared in this video is provided for educational purposes only. Any trades placed upon reliance of SharperTrades.com are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, commodities, options and forex, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. This is not an offer to buy or sell stocks, forex, futures, options, commodity interests or any other trading security.

Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020 Transcript: Click here Infographic: Click here Biogen tops market estimates in Q3, lowers guidance. Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated. Corporate Participants: Joe Mara — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock, Jr. — Executive Vice President Research & Development Michael McDonnell — Executive Vice President Chief Financial Officer Analysts: Terence Flynn — Goldman Sachs — Analyst Marc Goodman — SVB Leerink — Analyst Matthew Harrison — Morgan Stanley — Analyst Umer Raffat — Evercore ISI — Analyst Evan Seigerman — Credit Suisse — Analyst Phil Nadeau — Cowen & Company — Analyst Michael Yee — Jefferies — Analyst Cory Kasimov — JPMorgan — Analyst Ronny Gal — Bernstein — Analyst Geoff Meacham — Bank of America — Analyst Sumant Kulkarni — Canaccord — Analyst Jay Olson — Oppenheimer — Analyst Brian Abrahams — RBC Capital Markets — Analyst --- Send in a voice message: https://anchor.fm/earningspodcast/message Support this podcast: https://anchor.fm/earningspodcast/support

This week on the podcast Agustin dedicates the entirety of the episode to analyzing whether or not $BIIB has a cure for Alzheimer's. Warning there is a lot of science in this episode!Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros and Youtube!

One of the main benefits of being a part of the fitness community is the element of social cohesion, especially when it comes to group sports or group fitness events. Sadly, the MCO has put a pause on getting fit together… or has it? Sheyong Tan, co-founder and CEO of BiiB, shares how they brought group fitness events onto the digital space. Visit www.kurnia.com for more information on how Kurnia can support you through these trying times.

One of the main benefits of being a part of the fitness community is the element of social cohesion, especially when it comes to group sports or group fitness events. Sadly, the MCO has put a pause on getting fit together… or has it? Sheyong Tan, co-founder and CEO of BiiB, discusses how they’re bringing group fitness events onto the digital space, and their Men vs Women Charity Challenge to sponsor PPE for frontliners.

One of the main benefits of being a part of the fitness community is the element of social cohesion, especially when it comes to group sports or group fitness events. Sadly, the MCO has put a pause on getting fit together… or has it? Sheyong Tan, co-founder and CEO of BiiB, discusses how they’re bringing group fitness events onto the digital space, and their Men vs Women Charity Challenge to sponsor PPE for frontliners.

Před 76 lety, v noci z 8. na 9. března 1944, zahubila nacistická likvidační mašinérie v plynových komorách v Osvětimi-Birkenau více než 3700 obyvatel tzv. terezínského rodinného tábora (úředním označením tábora BIIb).

As stocks hit new all-time highs to finish 2019, the professional money managers were busy positioning their portfolios for 2020. What were they buying, and selling, heading into the new year?   (0:20) - What Are The Large Investment Firms Buying? (2:45) - Tesla To $7000: Who’s Buying? (15:20) - Is It Time To Get Back Into Micron? (21:30) - Buying Into The Healthcare Industry (29:50) - Berkshire Hathaway 13-F  (38:45) - Episode Roundup: MU, TSLA, PSX, TRV, WFC, KR, BIIB, GME BBBY, MAXR, SPY, VOO, SQ, ILMN Podcast@Zacks.com

Hey everybody, in this episode I give updates on Trevena, Marker Therapeutics, and Biogen. I also touch on recent Alzheimer's failures by Lilly and Roche. I wrap up the episode talking about some of the 13F filings from various hedge funds/advisors and what it could mean for our favorite biotechs.Follow me on twitter @matthewlepoire Email me at matthewlepoire@gmail.com www.breakingbiotech.comDisclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech

In this episode, you'll learn:What is the intrinsic value of Biogen, GrafTech, Allstate, and i3 VerticalsIf Mohnish Pabrai’s newest stock pick GrafTech is a good investmentWhy you would want to buy a put option and not write the put option when you short a stockHow to value a pharmaceutical companyUnderstanding the cycles in the insurance industry Ask The Investors: How do you estimate growth rates? BOOKS AND RESOURCES MENTIONED IN THIS EPISODEPreston and Stig’s FREE resource, Intrinsic Value IndexSubscribe to Preston and Stig’s FREE Intrinsic Value AssessmentsPreston and Stig’s tool for stock selection and determining the momentum, TIP Finance Join the Mastermind Group and the TIP Community for the Berkshire Hathaway Annual Shareholder’s MeetingWarren Buffett’s letters to shareholdersTobias Carlisle’s podcast, The Acquires PodcastTobias Carlisle's book, The Acquirer's Multiple - Read reviews of the bookTobias Carlisle’s Acquirer’s Multiple stock screener: AcquirersMultiple.comTweet directly to Tobias CarlisleTweet directly to HariDownload your free audio book at Audible.Find the best job candidate at Ziprecruiter.Discover CMC Markets, the ultimate platform for online trading on mobile and desktop.Move your business to the cloud with Netsuite.Automate your work with Zapier.Experience a real estate investing platform that is powered by an investor-first model with Fundrise. Solve your long list of must-reads once and for all with Blinkist.

PreMarket Prep is a live trading talk show that airs weekdays from 8-9 am ET on YouTube as well as http://premarket.benzinga.com/pre-market-show/ Check out our chat rooms to get your questions answered on the show! We pride ourselves on being the best source of premarket trading strategy, and we feature some of Wall Street’s best traders as guests. On today’s show, we discuss…. - X cutting its dividend and lowering guidance - BIIB announcing a buyback - Earnings reactions from NKE, WGO, and BB Featured Guests: Alan Brochstein, Author of "420 Investor" founding partner of New Cannabis Ventures (34:15) Meet the Hosts: Dennis Dick Bio: http://www.premarketprep.com/author/premarketinfo/ Twitter: https://twitter.com/TripleDTrader Joel Elconin Bio: http://www.premarketprep.com/author/joelelconin/ Twitter: https://twitter.com/Spus Tune in to the show live or via podcast! iTunes: https://itunes.apple.com/us/podcast/benzinga-tv Soundcloud: https://soundcloud.com/bztv Stitcher: https://www.stitcher.com/podcast/benzinga-morning-show TuneIn: https://tunein.com/podcasts/Business--Economics/Benzinga-TV-p1006070/ Google Play: https://play.google.com/music/listen?u=0#/ps/Id2myc5nfdgd4pry47sjss2n2my Like the show? Keep up with all Benzinga news! Visit https://www.benzinga.com/ to subscribe to our newsletter Visit https://twitter.com/Benzinga to follow us on Twitter Visit https://www.facebook.com/Benzinga/ to like us on Facebook Be sure to check out https://pro.benzinga.com/. Benzinga’s real-time news platform with all the information you need to invest better today.

Stock Market Direction: A review of the 7 index ETFs we monitor with our proprietary Algorithms to determine stock market direction and risk exposure. (SPY QQQ DIA IWM MTUM VLUE FFTY) Cannabis Couch: CWEB.ca secondary, ACB completes convert & OGI earnings released. How to identify the correct buy point for a stock:Rule #2 from the ARMR Report Stock Market Investing playbook (DIS, CERN, BIIB)           (Rule #1 revealed here: https://www.youtube.com/watch?v=22Q85NkjTMU&t=1598s)                                                                            The ARMR Report covers the secrets of successful Stock Market investing through the vector of Fundamental / Technical research and algorithmic execution  DISCLAIMER: All of ARMRreport, our trades, strategies, and news coverage are based on our opinions alone and are only for educational purposes. You should not take any of this information as guidance for buying or selling any type of investment or security. I am only sharing my biased opinion based off of speculation and personal experience.  An individual trader's/investor's results may not be typical and may vary from person to person. It is important to keep in mind that there are risks associated with investing in the stock market and that one can lose all of their investment. Thus, trades/investments should not be based on the opinions of others but by your own research and due diligence.

In which we welcome our new commentator Wiktoria, and discuss the new BIIB shuck and jive.

If you don't want to wait until we publish it on this podcast, use our app to listen right away. Our app publishes these earnings calls shortly after they are available. We've created a dedicated earnings calls listening app with a library of thousands of calls. Our app lets you set "new call" notifications, download earnings calls, and see the date of the earnings call. Behind the Scenes Podcast: "Entrepreneur Talk" - https://podcasts.apple.com/us/podcast/entrepreneur-talk/id1387042950 App Store: https://itunes.apple.com/us/app/borsa-earnings-calls/id1414117603?mt=8 Google Play Store: https://play.google.com/store/apps/details?id=com.borsahq.earningscalls Weekly Email List (week's earnings calls, product updates, special offers, etc.): http://eepurl.com/dCZ5AH Video Demo: https://www.youtube.com/watch?v=OALinunnRjc&t=20s Welcome to Earnings Season. Our goal is to make listening to earnings calls easier. We upload relevant and newsworthy earnings calls for easy listening. To request a company's earnings call, email borsaHQ@gmail.com. App Store Play Store Twitter Instagram StockTwits

PreMarket Prep is a live trading talk show that airs weekdays from 8-9 am ET on YouTube as well as http://premarket.benzinga.com/pre-market-show/ Check out our chat rooms to get your questions answered on the show! We pride ourselves on being the best source of premarket trading strategy, and we feature some of Wall Street’s best traders as guests. On today’s show, we discuss…. - Trading in AAPL ahead of its event today - BIIB's buyback - Analyst commentary on HIBB, TSLA, and AKAM Featured Guests: Jake Wujastyk, TrendSpider (34:30) Meet the Hosts: Dennis Dick Bio: http://www.premarketprep.com/author/premarketinfo/ Twitter: https://twitter.com/TripleDTrader Joel Elconin Bio: http://www.premarketprep.com/author/joelelconin/ Twitter: https://twitter.com/Spus Tune into the show live or via podcast! iTunes: https://itunes.apple.com/us/podcast/benzinga-tv Soundcloud: https://soundcloud.com/bztv Stitcher: https://www.stitcher.com/podcast/benzinga-morning-show TuneIn: https://tunein.com/podcasts/Business--Economics/Benzinga-TV-p1006070/ Google Play: https://play.google.com/music/listen?u=0#/ps/Id2myc5nfdgd4pry47sjss2n2my Like the show? Keep up with all Benzinga news! Visit https://www.benzinga.com/ to subscribe to our newsletter Visit https://twitter.com/Benzinga to follow us on Twitter Visit https://www.facebook.com/Benzinga/ to like us on Facebook Be sure to check out https://pro.benzinga.com/. Benzinga’s real-time news platform with all the information you need to invest better today.

Here's why Roche's acquisition of gene therapy pioneer Spark Therapeutics and Biogen's acquisition of gene therapy upstart Nightstar Therapeutics could put Regenxbio in play. RHHBY, ONCE, BIIB, NITE, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Ryan Christensen, account executive at Adviser Investments, has the market analysis for Tuesday, July 24. The Dow Jones Industrial Average and S&P 500 gained 0.8% and 0.5%, respectively, while the NASDAQ Composite declined fractionally. For earnings, we saw Biogen (ticker: BIIB) top expectations with 15% earnings per share growth and 9% revenue advances. BIIB closed the day up nearly 6%. Investors continue to react favorably to Biogen’s stock as the company is scheduled to present clinical trials on its experimental BAN2401 therapy at this week’s Alzheimer’s Association International Conference.

Please pick a time stamped topic below: (0:20) - SEC 13F Filings (1:35) - Snapchat Buying Spree: SNAP, FB (7:30) - Energy Stock Slowdown: COP (8:40) - 2017 Semiconductor Boom: NVDA, MU, AMAT (14:20) - Warren Buffett is Still Buying Airline Stocks: LUV, AARL, DAL (17:20) - Alibaba Makes New Highs and China Rebounds: WEIBO, SINA (20:00) - Healthcare Sector: PRGO, AMGN, BIIB (24:40) - Little to No Movement in Banking Sector: GS (26:30) - Episode Roundup: Podcast@Zacks.com

Major U.S. indices gave us a split decision for the day as Oil hit a key benchmark.Featured Topics: The Stock Market, Oil Prices, Winners, Losers, MRO, CXO, EOG, Good News, Bad NewsFeatured Stocks: EOG, CXO, MRO, BIIB, TRIP, ALXNWhat's the right way to buy oil? Is Trip Advisor trippin? How are indices holding up month to date.Follow on Twitter: Twitter.com/TuskMediaLLC

Major U.S. indices are up on the day as oil hits a benchmark. Featured Topics: The Stock Market, American Airlines, Biogen, Ralph Lauren, Oil, 50 Cent Featured Stocks: AAL, BIIB, RL How's the market holding up a day after the Federal Reserve said some words? Is oil going to stay north of $50? What's up with American Airlines new customer-friendly policy?Follow on Twitter: Twitter.com/TuskMediaLLC